504 results on '"Brice, Pauline"'
Search Results
2. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
3. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
4. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
5. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study
6. Classical Hodgkin lymphoma
7. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
8. Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
9. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
10. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
11. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients
12. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
13. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial
14. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
15. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
16. Skin involvement in systemic lymphoma of follicular helper T‐cell origin: A cohort study of 57 patients.
17. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO 16 LYMPHOVIR Cohort
18. O-129 - Skin involvement in systemic lymphoma of follicular helper T-cell origin: a cohort study of 57 patients
19. 18F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin
20. Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients
21. Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma
22. Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis
23. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
24. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
25. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
26. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts
27. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
28. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
29. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma
30. Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)
31. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
32. Strong Correlations of Anti–Viral Capsid Antigen Antibody Levels in First-Degree Relatives from Families with Epstein-Barr Virus–Related Lymphomas
33. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC
34. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
35. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome
36. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
37. Lenalidomide is safe and active in Waldenström macroglobulinemia
38. Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
39. Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study
40. Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma
41. PET2-driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP
42. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly
43. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis
44. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial
45. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
46. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
47. 18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
48. Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma: Long-Term Economic Evaluation
49. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients
50. Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.